Skip to content

Alkermes

US · ALKS #1780 by market cap Listed 1970
44.94 -1.24 -2.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 8 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.7 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
109.98% +0.66pp
Institutions
511 -8
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund72.41%
Hedge Fund25.58%
VC/PE Fund4.22%
Public Company2.86%
Government Pension Fund1.61%
Individual/Insider1.48%
Sovereign Wealth Fund1.29%
Private Company0.90%
Insurance Company0.73%

Top holders as of 2026-09-30

BlackRock 17.08% · 28.70M sh
State Street Global Advisors 6.03% · 10.13M sh
Baker Bros. Advisors LP 5.96% · 10.01M sh
Vanguard Portfolio Management, LLC 5.63% · 9.46M sh
T. Rowe Price Group, Inc. 4.66% · 7.83M sh
Vanguard Capital Management, LLC 4.47% · 7.50M sh
Renaissance Technologies Corp. 3.86% · 6.49M sh
Geode Capital Management, LLC 2.64% · 4.44M sh
Deep Track Capital, LP 2.38% · 4.00M sh
Dimensional Fund Advisors 2.50% · 4.19M sh
Holocene Advisors, LP 2.14% · 3.60M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 23 buys · 27 sells

NameRoleStake
Richard Pops Chairperson 0.82%
Blair Jackson Chief Executive Officer 0.14%
David Gaffin Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary 0.13%
David Daglio Former Independent Director 0.06%
Shane Cooke Independent Director 0.06%
Christian Nichols Chief Commercial Officer 0.06%
Craig Hopkinson Executive VP of Research & Development and Chief Medical Officer 0.04%
Brian McKeon Independent Director 0.03%
Nancy Snyderman Independent Director 0.02%
Frank Wilson Lead Independent Director 0.02%
Richard Brian Gaynor Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-02 David Gaffin Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Automatic Disposition -2,035 $46.17
2026-10-07 Joshua Reed Senior Vice President Derivative Exercise and Sale -4,069 $40.11
2026-10-07 Joshua Reed Senior Vice President Derivative Exercise and Retained +5,095 --
2026-10-06 Anne Michelle Whitaker Independent Director Other Derivative Acquisition +7,239 --
2026-10-06 Anne Michelle Whitaker Independent Director Other Derivative Acquisition +17,998 $41.45
2026-10-01 David Gaffin Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Automatic Disposition -2,034 $41.03
2026-09-02 David Gaffin Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Automatic Disposition -2,034 $48.01
2026-08-31 Craig Hopkinson Executive VP of Research & Development and Chief Medical Officer Automatic Disposition -4,000 $46.99
2026-08-31 Craig Hopkinson Executive VP of Research & Development and Chief Medical Officer Derivative Exercise and Sale -5,000 $24.59–46.99
2026-08-16 Christian Nichols Chief Commercial Officer Automatic Disposition -7,576 $49.19–49.65
2026-08-04 Blair Jackson Chief Executive Officer Other Derivative Acquisition +217,534 $49.61
2026-08-02 Nancy Snyderman Independent Director Derivative Exercise and Sale -44,472 $46.72–50.35
2026-08-02 Craig Hopkinson Executive VP of Research & Development and Chief Medical Officer Automatic Disposition -4,000 $48.58
2026-08-02 Craig Hopkinson Executive VP of Research & Development and Chief Medical Officer Derivative Exercise and Sale -5,000 $19.34–48.58
2026-08-02 David Gaffin Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Automatic Disposition -2,034 $48.58
2026-07-05 David Gaffin Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Automatic Disposition -2,034 $54.03
2026-06-30 Craig Hopkinson Executive VP of Research & Development and Chief Medical Officer Automatic Disposition -4,000 $51.46–52.13
2026-06-30 Craig Hopkinson Executive VP of Research & Development and Chief Medical Officer Derivative Exercise and Sale -5,000 $19.34–51.46
2026-06-11 Christopher I. Wright Independent Director Automatic Disposition -2,000 $45.10
2026-06-03 David Gaffin Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Automatic Disposition -2,034 $43.05

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:09 · For reference only, not investment advice and not tailored to your situation.

Alkermes discussion 0 comments

Add a comment